Lingqing Xu

Dr. Lingqing Xu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2021 in mSphere
Verified
Journal Article
Open access
MAMohamed El-Sayed Ahmed
Mohamed El-Sayed Ahmed
YYYanxian Yang
Yanxian Yang
YYYongqiang Yang
Yongqiang Yang
BYBin Yan
Bin Yan
GCGuanping Chen
Guanping Chen
GTGuo-Bao Tian
Guo-Bao Tian
CRKP has been registered in the critical priority tier by the World Health Organization and has become a significant menace to public health. The emergence of CR-HvKP is of great concern in terms of both disease and treatment.

9 November 2020 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
JCJia-Jie Chen
Jia-Jie Chen
LZLi-Na Zhang
Li-Na Zhang
HHHu Hou
Hu Hou
LXLingqing Xu
Lingqing Xu
KJkunmei Ji
kunmei Ji
A severe immune response in patients with coronavirus disease 2019 (COVID‑19) can cause a potentially lethal unconstrained inflammatory cytokine storm, known as cytokine release syndrome (CRS). The present study provides an overview of the biology underlying CRS and how targeted inhibition of interleukin (IL)‑6 signaling may improve outcomes and the survival of patients suffering from COVID‑19. Preliminary clinical results have indicated that antagonism of the IL‑6 receptor (IL‑6R), including with the FDA‑approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical COVID‑19 while maintaining a good safety profile. The available clinical data support the expansion of clinical trials using IL‑6R targeting inhibitors for severe and critical COVID‑19 treatment.

12 November 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
YLYing Luo
Ying Luo
YXYing Xue
Ying Xue
QLQun Lin
Qun Lin
LMLiyan Mao
Liyan Mao
GTGuoxing Tang
Guoxing Tang
Feng WangFeng Wang
Feng Wang
Background: The differential diagnosis between tuberculous meningitis (TBM) and bacterial meningitis (BM) remains challenging in clinical practice. This study aimed to establish a diagnostic model that could accurately distinguish TBM from BM.Methods: Patients with TBM or BM were recruited between January 2017 and January 2021 at Tongji Hospital (Qiaokou cohort) and Sino-French New City Hospital (Caidian cohort). The detection for indicators involved in cerebrospinal fluid (CSF) and T-SPOT assay were performed simultaneously. Multivariate logistic regression was used to create a diagnostic model.Results: A total of 174 patients (76 TBM and 98 BM) and another 105 cases (39 TBM and 66 BM) were enrolled from Qiaokou cohort and Caidian cohort, respectively. Significantly higher level of CSF lymphocyte proportion while significantly lower levels of CSF chlorine, nucleated cell count, and neutrophil proportion were observed in TBM group when comparing with those in BM group. However, receiver operating characteristic (ROC) curve analysis showed that the areas under the ROC curve (AUCs) produced by these indicators were all under 0.8. Meanwhile, tuberculosis-specific antigen/phytohemagglutinin (TBAg/PHA) ratio yielded an AUC of 0.889 (95% CI, 0.840–0.938) in distinguishing TBM from BM, with a sensitivity of 68.42% (95% CI, 57.30%–77.77%) and a specificity of 92.86% (95% CI, 85.98%–96.50%) when a cutoff value of 0.163 was used. Consequently, we successfully established a diagnostic model based on the combination of TBAg/PHA ratio, CSF chlorine, CSF nucleated cell count, and CSF lymphocyte proportion for discrimination between TBM and BM. The established model showed good performance in differentiating TBM from BM (AUC: 0.949; 95% CI, 0.921–0.978), with 81.58% (95% CI, 71.42%–88.70%) sensitivity and 91.84% (95% CI, 84.71%–95.81%) specificity. The performance of the diagnostic model obtained in Qiaokou cohort was further validated in Caidian cohort. The diagnostic model in Caidian cohort produced an AUC of 0.923 (95% CI, 0.867–0.980) with 79.49% (95% CI, 64.47%–89.22%) sensitivity and 90.91% (95% CI, 81.55%–95.77%) specificity.Conclusions: The diagnostic model established based on the combination of four indicators had excellent utility in the discrimination between TBM and BM.

29 September 2023 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
JLJianmei Lai
Jianmei Lai
ZLZhishan Li
Zhishan Li
LPLixin Pan
Lixin Pan
YHYunxia Huang
Yunxia Huang
ZZZifei Zhou
Zifei Zhou
LXLingqing Xu
Lingqing Xu

6 March 2025 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
ZLZhihong Li
Zhihong Li
TZTongtong Zhang
Tongtong Zhang
ZWZiqi Wang
Ziqi Wang
SHShuqiang Huang
Shuqiang Huang
CTCuiyu Tan
Cuiyu Tan
LXLingqing Xu
Lingqing Xu
Background: Pseudomonas aeruginosa is a common gram-negative opportunistic pathogen that is now commonly treated with carbapenems, such as Meropenem. However, the increasing rate of emergence of heteroresistant strains poses a therapeutic challenge. Therefore, we examined the antibacterial activity of Sodium houttuyfonate (SH, a compound derived from Houttuynia cordata) in combination with Meropenem (MEM) against heteroresistant Pseudomonas aeruginosa and investigated the mechanism of Sodium houttuyfonate.Methods: Heteroresistant Pseudomonas aeruginosa was used as the experimental strain for the study and the combined action activity of the two drugs was inves-tigated by determining the Minimum Inhibitory Concentration (MIC), Fractional Inhibitory Concentration Index (FICI), and time killing curves. Also the effect of Sodium houttuyfonate on biofilm as well as bacterial swimming motility assay was investigated by crystal violet staining of bacterial biofilm, microanalysis of biofilm, bacterial swimming motility assay, quantitative real-time PCR (qRT-PCR) and population sensing related virulence factors.Results: For the screened experimental strains, the MIC of SH was 4,000 μg/ml; the FICI of both drugs on the four experimental strains was ≤0.5, which showed a synergistic effect. When SH ≥ 250 μg/ml, it was able to effectively inhibit bacterial biofilm formation as well as swimming ability compared with the blank control group. In the qRT-PCR experiment, the expression of biofilm formation-related genes (pslA, pelA, aglD, lasI, lasR, and rhlA) and swimming ability-related genes (fliC, pilZ, and pilA) were decreased in the SH-treated group, compared with the blank control group.Conclusion: Our study demonstrated that Sodium houttuyfonate and Meropenem exhibited synergistic inhibition against heteroresistant Pseudomonas aeruginosa, and that Sodium houttuyfonate may achieve its inhibitory effect by inhibiting bacterial biofilm formation, inhibiting motility, and down-regulating related genes.

15 June 2026 in mSphere
Verified
Journal Article
Open access
XDXue Deng
Xue Deng
CSCong Shen
Cong Shen
LCLingjuan Chen
Lingjuan Chen
DSDandan Sun
Dandan Sun
TQTian Qiu
Tian Qiu
LZLan-lan Zhong
Lan-lan Zhong
The plasmid-borne mcr-1 gene poses a significant threat to global health by conferring resistance to colistin, a critical last-resort antibiotic. While its spread is well documented, the adaptations enabling its concurrent antibiotic resistance and clinical pathogenicity remain unknown. The metabolism of bacterial pathogens has evolved to support virulence in nutrient-limiting host environments. Here, we show that sorbose metabolism promotes the fitness and virulence of mcr-1- positive Escherichia coli (MCRPEC), but does not affect its resistance to colistin or polymyxin B. Notably, the virulence contribution is also observed in an mcr-1 -negative background. Genetic disruption of sorbose catabolism (Δ sorD ) attenuated MCRPEC virulence and fitness both in vitro and in vivo . Integrated transcriptomic and metabolomic analyses suggest that this attenuation is associated with impaired expression of two major virulence determinants. First, defective sorbose metabolism limits the supply of monosaccharide precursors required for LPS biosynthesis, leading to reduced LPS content. Second, metabolic disruption decreases intracellular cAMP levels, which downregulates fimH expression via a cAMP-dependent signaling pathway, thereby compromising bacterial adhesion. Notably, although sorD deletion enhances biofilm formation, this increase is insufficient to rescue the in vivo virulence defect. Restoration of the sorbose metabolic pathway partially rescues MCRPEC pathogenicity. These findings suggest that sorbose metabolism contributes to MCRPEC pathogenicity by supporting LPS synthesis and regulating fimH expression via cAMP signaling. This study indicates a metabolic link between sorbose utilization and MCRPEC pathogenicity, raising the possibility that sorbose, a common food additive, could facilitate MCRPEC pathogenicity. IMPORTANCE: The spread of colistin-resistant Escherichia coli ( E. coli ) limits treatment options for life-threatening infections. This study shows that sorbose metabolism, which utilizes a common dietary sugar, contributes to the fitness and virulence of such resistant bacteria without affecting their colistin resistance. Using mcr-1 -positive E. coli , we find that this metabolic pathway supports lipopolysaccharide synthesis and, via a cAMP-dependent mechanism, promotes bacterial adhesion. Disabling sorbose catabolism attenuates the pathogen in animal models. These findings suggest a previously unrecognized link between a specific carbohydrate metabolism and pathogenesis in drug-resistant E. coli , raising the possibility that dietary components may influence infection outcomes.